The 5-HT3receptor as a therapeutic target
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
The 5-HT3 receptor is a neurotransmitter-gated ion channel. It is a member of the Cys-loop family of receptors, which also includes nicotinic acetylcholine, glycine and GABAA receptors. Each member of the family consists of an arrangement of five subunits surrounding a central ion-conducting pore. The 5-HT3 receptor binding site is composed of six loops from two adjacent subunits, and the critical ligand binding residues within these loops are well documented. There are a range of 5-HT3 receptor agonists and competitive antagonists, but it is the antagonists that dominate their clinical use. Studies have proposed a range of disease symptoms that might be amenable to 5-HT3 receptor selective compounds; however, so far only the treatment of emesis and irritable bowel syndrome have been fully realised. In this review, the authors look at the structure, function and distribution of 5-HT3 receptors and how this may influence their role in disease. The authors also describe the existing clinical applications of 5-HT3 antagonists and the future potential of these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Granisetron prevents nausea and vomiting during spinal anaesthesia for caesarean section
Fujii, Y., Tanaka, H. Y., & Toyooka, H. (1998) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1998.tb04922.x · Cited by 38
RetractedMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors
Brejc, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van der Oost, J., Smit, A. B., & Sixma, T. K. (2001) · Nature · doi:10.1038/35077011 · Cited by 1,759
Structure and gating mechanism of the acetylcholine receptor pore
Miyazawa, A., Fujiyoshi, Y., & Unwin, N. (2003) · Nature · doi:10.1038/nature01748 · Cited by 1,270
Primary Structure And Functional Expression of the 5HT 3 Receptor, A Serotonin-gated Ion Channel
Maricq, A. V., Peterson, A. S., Brake, A. J., Myers, R. M., & Julius, D. (1991) · Science · doi:10.1126/science.1718042 · Cited by 979
American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9591 · Cited by 740
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
5-HT3 receptors are membrane ion channels
Derkach, V., Surprenant, A., & North, R. A. (1989) · Nature · doi:10.1038/339706a0 · Cited by 625
A BIOCHEMICAL AND PHARMACOLOGICAL SUGGESTION ABOUT CERTAIN MENTAL DISORDERS
Woolley, D. W., & Shaw, E. (1954) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.40.4.228 · Cited by 602
Mertz, H., Morgan, V., Tanner, G., Pickens, D., Price, R., Shyr, Y., & Kessler, R. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70170-3 · Cited by 586
The 5-HT3B subunit is a major determinant of serotonin-receptor function
Davies, P. A., Pistis, M., Hanna, M. C., Peters, J. A., Lambert, J. J., Hales, T. G., & Kirkness, E. F. (1999) · Nature · doi:10.1038/16941 · Cited by 561
Cis–trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel
Lummis, S. C. R., Beene, D. L., Lee, L. W., Lester, H. A., Broadhurst, R. W., & Dougherty, D. A. (2005) · Nature · doi:10.1038/nature04130 · Cited by 456
Self-citationRole of serotonin in memory impairment.
Buhot, M.-C., Martin, S., & Segu, L. (2000) · Annals of Medicine · doi:10.3109/07853890008998828 · Cited by 419
Johnson, B. A., Roache, J. D., Javors, M. A., DiClemente, C. C., Cloninger, C. R., Prihoda, T. J., Bordnick, P. S., Ait-Daoud, N., & Hensler, J. (2000) · JAMA · doi:10.1001/jama.284.8.963 · Cited by 414
Nervous system distribution of the serotonin 5-HT3 receptor mRNA.
Tecott, L. H., Maricq, A. V., & Julius, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.4.1430 · Cited by 368
Aapro, M. S., Grunberg, S. M., Manikhas, G. M., Olivares, G., Suarez, T., Tjulandin, S. A., Bertoli, L. F., Yunus, F., Morrica, B., Lordick, F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl137 · Cited by 338
DRUGS WHICH ANTAGONIZE 5‐HYDROXYTRYPTAMINE
GADDUM, J. H., & HAMEED, K. A. (1954) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1954.tb00848.x · Cited by 293
Analgesic effect of acetaminophen in humans: First evidence of a central serotonergic mechanism
PICKERING, G., LORIOT, M., LIBERT, F., ESCHALIER, A., BEAUNE, P., & DUBRAY, C. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.307 · Cited by 283
Dubin, A. E., Huvar, R., D'Andrea, M. R., Pyati, J., Zhu, J. Y., Joy, K. C., Wilson, S. J., Galindo, J. E., Glass, C. A., Luo, L., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30799 · Cited by 281
A cytoplasmic region determines single-channel conductance in 5-HT3 receptors
Kelley, S. P., Dunlop, J. I., Kirkness, E. F., Lambert, J. J., & Peters, J. A. (2003) · Nature · doi:10.1038/nature01788 · Cited by 273
Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel
Bouzat, C., Gumilar, F., Spitzmaul, G., Wang, H.-L., Rayes, D., Hansen, S. B., Taylor, P., & Sine, S. M. (2004) · Nature · doi:10.1038/nature02753 · Cited by 267
Niesler, B., Frank, B., Kapeller, J., & Rappold, G. A. (2003) · Gene · doi:10.1016/s0378-1119(03)00503-1 · Cited by 252
Drugs for preventing postoperative nausea and vomiting
Carlisle, J., & Stevenson, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004125.pub3 · Cited by 244
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
Delvaux, M., Louvel, D., Mamet, J. ‐., Campos‐Oriola, R., & Frexinos, J. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00375.x · Cited by 236 · cited 1×
“2 Irritable bowel syndrome and intestinal effects The 5-HT3 receptor antagonist alosetron is an effective treatment for irritable bowel syndrome as it decreases gut transit [61], increases fluid absorption [62] and reduces pain in irritable bowel syndrome patients [63-65].”
BackgroundThompson, A., & R. Lummis, S. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778522029 · Cited by 230
Self-citationReeves, D. C., & Lummis, S. C. R. (2002) · Molecular Membrane Biology · doi:10.1080/09687680110110048 · Cited by 193
Self-citationMiyake, A., Mochizuki, S., Takemoto, Y., & Akuzawa, S. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10488-4 · Cited by 181
Morales, M., & Wang, S.-D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-15-06732.2002 · Cited by 175
The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro
Wong, E. H. F., Clark, R. D., Leung, E., Loury, D. J., Bonhaus, D. W., Jakeman, L. B., Parnes, H. L., Whiting, R. L., & Eglen, R. M. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13282.x · Cited by 169
Schwörer, H., Hartmann, H., & Ramadori, G. (1995) · Pain · doi:10.1016/0304-3959(94)00145-5 · Cited by 165
Tremblay, P.-B., Kaiser, R., Sezer, O., Rösler, N., Schelenz, C., Possinger, K., Roots, I., & Brockmöller, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.164 · Cited by 157
Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor
Eisensamer, B., Rammes, G., Gimpl, G., Shapa, M., Ferrari, U., Hapfelmeier, G., Bondy, B., Parsons, C. G., Gilling, K. E., Zieglgänsberger, W., et al. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001314 · Cited by 139
Minami, M., Endo, T., Hirafuji, M., Hamaue, N., Liu, Y., Hiroshige, T., Nemoto, M., Saito, H., & Yoshioka, M. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00057-3 · Cited by 134
Ligand‐gated ion channels in the enteric nervous system
Galligan, J. J. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00363.x · Cited by 133
Niesler, B., Flohr, T., Nöthen, M. M., Fischer, C., Rietschel, M., Franzek, E., Albus, M., Propping, P., & Rappold, G. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200108000-00002 · Cited by 131
Jones, Holtmann, Rodrigo, Ehsanullah, Crompton, Jacques, & Mills (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00678.x · Cited by 131
Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice
Kelley, S. P., Bratt, A. M., & Hodge, C. W. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02960-6 · Cited by 130
Tropisetron improves deficits in auditory P50 suppression in schizophrenia
Koike, K., Hashimoto, K., Takai, N., Shimizu, E., Komatsu, N., Watanabe, H., Nakazato, M., Okamura, N., Stevens, K. E., Freedman, R., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.016 · Cited by 127
Miquel, M. ‐., Emerit, M. B., Nosjean, A., Simon, A., Rumajogee, P., Brisorgueil, M. ‐., Doucet, E., Hamon, M., & Vergé, D. (2002) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01872.x · Cited by 125
Kia, H. K., Miquel, M., McKernan, R. M., Laporte, A., Lombard, M., Bourgoin, S., Hamon, M., & Vergé, D. (1995) · Neuroreport · doi:10.1097/00001756-199501000-00008 · Cited by 112
Ondansetron reduces the craving of biologically predisposed alcoholics
Johnson, B. A., Roache, J. D., Ait‐Daoud, N., Zanca, N. A., & Velázquez, M. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1002-9 · Cited by 109
5-HT3 receptor antagonists and anxiety; a preclinical and clinical review
Olivier, B., van Wijngaarden, I., & Soudijn, W. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00065-6 · Cited by 109
Weißhaar, E., Kucenic, M., & Fleischer, A. B. (2003) · Acta Dermato Venereologica · doi:10.1080/00015555-0369 · Cited by 106
The serotonin receptors : from molecular pharmacology to human therapeutics
Roth, B. L. (2006) · Cited by 101
Hussy, N., Lukas, W., & JONES, K. A. (1994) · The Journal of Physiology · doi:10.1113/jphysiol.1994.sp020441 · Cited by 101
Piche, T., Vanbiervliet, G., Cherikh, F., Antoun, Z., Huet, P. M., Gelsi, E., Demarquay, J.-F., Caroli-Bosc, F.-X., Benzaken, S., Rigault, M.-C., et al. (2005) · Gut · doi:10.1136/gut.2004.055251 · Cited by 101
Prediction of 5-HT3 Receptor Agonist-Binding Residues Using Homology Modeling
Reeves, D. C., Sayed, M., Chau, P. ‐., Price, K. L., & Lummis, S. C. R. (2003) · Biophysical Journal · doi:10.1016/s0006-3495(03)75039-5 · Cited by 99
Self-citationThe Non-Antiemetic Uses of Serotonin 5-HT3 Receptor Antagonists
Greenshaw, A. J., & Silverstone, P. H. (1997) · Drugs · doi:10.2165/00003495-199753010-00003 · Cited by 96
Harro, J., Häidkind, R., Harro, M., Modiri, A., Gillberg, P., Pähkla, R., Matto, V., & Oreland, L. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00043-7 · Cited by 96
Hodge, C. W., Samson, H. H., Lewis, R. S., & Erickson, H. L. (1993) · Alcohol · doi:10.1016/0741-8329(93)90034-l · Cited by 94
Brady, C., Stanford, I. M., Ali, I., Lin, L., Williams, J. M., Dubin, A. E., Hope, A. G., & Barnes, N. M. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00074-0 · Cited by 92
A cluster of novel serotonin receptor 3-like genes on human chromosome 3
Karnovsky, A., Gotow, L. F., McKinley, D. D., Piechan, J. L., Ruble, C., Mills, C. J., Schellin, K. A. B., Slightom, J. L., Fitzgerald, L. R., Benjamin, C. W., et al. (2003) · Gene · doi:10.1016/s0378-1119(03)00803-5 · Cited by 89
Bhatnagar, S., Nowak, N., Babich, L., & Bok, L. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.01.018 · Cited by 86
Antidepressants and Antipsychotic Drugs Colocalize with 5-HT3Receptors in Raft-Like Domains
Eisensamer, B., Uhr, M., Meyr, S., Gimpl, G., Deiml, T., Rammes, G., Lambert, J. J., Zieglgänsberger, W., Holsboer, F., & Rupprecht, R. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2460-05.2005 · Cited by 86
Expression of 5‐HT3Areceptors in cells of the immune system
Fiebich, B., Akundi, R., Seidel, M. F., et al. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410006952 · Cited by 84
Improved P50 Auditory Gating With Ondansetron in Medicated Schizophrenia Patients
Adler, L. E., Cawthra, E. M., Donovan, K. A., Harris, J. G., Nagamoto, H. T., Olincy, A., & Waldo, M. C. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.386 · Cited by 82
Iidaka, T., Ozaki, N., Matsumoto, A., Nogawa, J., Kinoshita, Y., Suzuki, T., Iwata, N., Yamamoto, Y., Okada, T., & Sadato, N. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5261-04.2005 · Cited by 80
Reeves, D. C., Goren, E. N., Akabas, M. H., & Lummis, S. C. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106066200 · Cited by 79
Self-citationGR38032F, a serotonin 5-HT3 antagonist, fails to alter cocaine self-administration in rats
Peltier, R., & Schenk, S. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90410-4 · Cited by 76
Alosetron and irritable bowel syndrome
Mayer, E. A., & Bradesi, S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.2089 · Cited by 74
Locating an Antagonist in the 5-HT3 Receptor Binding Site Using Modeling and Radioligand Binding
Thompson, A. J., Price, K. L., Reeves, D. C., Chan, S. L.-F., Chau, P. ‐., & Lummis, S. C. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413610200 · Cited by 73
Self-citationvan Wijngaarden, I., Hamminga, D., van Hes, R., Standaar, P. J., Tipker, J., Tulp, M. T. M., Mol, F., Olivier, B., & Jonge, A. D. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00075a026 · Cited by 72
Serotonin receptor gene HTR3A variants in schizophrenic and bipolar affective patients.
Niesler, B., Weiß, B., Fischer, C., Nöthen, M. M., Propping, P., Bondy, B., Rietschel, M., Maier, W., Albus, M., Franzek, E., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00003 · Cited by 72
A controlled trial of ondansetron in the pruritus of cholestasis
O'Donohue, J. W., Pereira, S. P., Ashdown, A. C., Haigh, C. G., Wilkinson, J. R., & Williams, R. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02430.x · Cited by 71
Tzvetkov, M. V., Meineke, C., Oetjen, E., Hirsch‐Ernst, K. I., & Brockmöller, J. (2006) · Gene · doi:10.1016/j.gene.2006.08.002 · Cited by 69
Kaiser, R., Tremblay, P.-B., Sezer, O., Possinger, K., Roots, I., & Brockm??ller, J. (2004) · Pharmacogenetics · doi:10.1097/00008571-200405000-00001 · Cited by 65
Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists
Schw�rer, H., & Ramadori, G. P. (1993) · Journal of Molecular Medicine · doi:10.1007/bf00184497 · Cited by 65
Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner
Rammes, G., Eisensamer, B., Ferrari, U., Shapa, M., Gimpl, G., Gilling, K. E., Parsons, C. G., Riering, K., Hapfelmeier, G., Bondy, B., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001490 · Cited by 65
Harrell, A. V., & Allan, A. M. (2003) · Learning & Memory · doi:10.1101/lm.56103 · Cited by 64
Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia
Späth, M., Stratz, T., Neeck, G., Kötter, I., Hammel, B., Amberger, C., Haus, U., Färber, L., Pongratz, D., & Müller, W. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410005818 · Cited by 63
Cappelli, A., Gallelli, A., Manini, M., Anzini, M., Mennuni, L., Makovec, F., Menziani, M. C., Alcaro, S., Ortuso, F., & Vomero, S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493461 · Cited by 61
Effects of Quinine, Quinidine, and Chloroquine on α9α10 Nicotinic Cholinergic Receptors
Ballestero, J. A., Plazas, P. V., Kracun, S., Gómez‐Casati, M. E., Taranda, J., Rothlin, C. V., Katz, E., Millar, N. S., & Elgoyhen, A. B. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014431 · Cited by 61
Potvin, S., Stip, E., & Roy, J.-Y. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000063501.97247.38 · Cited by 58
TREATMENT FOR IRRITABLE BOWEL SYNDROME
Hadley, S. K., & Gaarder, S. M. (1980) · Inpharma Weekly · doi:10.1007/bf03290989 · Cited by 57
van Hooft, J. A., Spier, A. D., Yakel, J. L., Lummis, S. C. R., & Vijverberg, H. P. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11456 · Cited by 57
Self-citationEvidence for a vagal pathophysiology for bulimia nervosa and the accompanying depressive symptoms
Faris, P. L., Eckert, E. D., Kim, S.-W., Meller, W. H., Pardo, J. V., Goodale, R. L., & Hartman, B. K. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.12.047 · Cited by 56
Modulation of Human 5-Hydroxytryptamine Type 3AB Receptors by Volatile Anesthetics and n-Alcohols
Stevens, R. J. N., Rüsch, D., Solt, K., Raines, D. E., & Davies, P. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085076 · Cited by 54
The role of serotonin in the pathophysiology of irritable bowel syndrome.
Crowell (2001) · The American Journal of Managed Care · Cited by 53
The Use of Antidepressants in Functional Gastrointestinal Disorders: New Uses for Old Drugs
Olden, K. W. (2005) · CNS Spectrums · doi:10.1017/s1092852900019866 · Cited by 50
Biological and Biophysical Aspects of Ligand-Gated Ion Channel Receptor Superfamilies
Monaghan, D., Boyle, J., BEAN, L. L., et al. (2006) · Cited by 48
Hope, A. G., Peters, J. A., Brown, A. M., Lambert, J. J., & Blackburn, T. P. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15529.x · Cited by 48
Binding Interactions of Antagonists with 5‐Hydroxytryptamine3AReceptor Models
Maksay, G., Bikádi, Z., & Simonyi, M. (2003) · Journal of Receptors and Signal Transduction · doi:10.1081/rrs-120025568 · Cited by 47
The role of serotonin in the pathophysiology of irritable bowel syndrome.
Crowell, M. D. (2001) · PubMed · Cited by 47
Peters, J. A., Malone, H. M., & Lambert, J. J. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13863.x · Cited by 46
Huang, J., Spier, A. D., & Pickel, V. M. (2004) · Brain Research · doi:10.1016/j.brainres.2004.09.009 · Cited by 45
Sudweeks, S. N., van Hooft, J. A., & Yakel, J. L. (2002) · The Journal of Physiology · doi:10.1113/jphysiol.2002.029736 · Cited by 42
CLAYTON, SARGENT, BUTLER, GALE, MAXWELL, HUNT, BARRETT, CAMBRIDGE, BOUNTRA, & HUMPHREY (1999) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.1999.00148.x · Cited by 40
Sandrini, M., Pini, L. A., & Vitale, G. (2003) · Inflammation Research · doi:10.1007/s00011-003-1185-5 · Cited by 40
Frank, G. K., Kaye, W. H., Weltzin, T. E., Perel, J., Moss, H., McConaha, C., & Pollice, C. (2001) · International Journal of Eating Disorders · doi:10.1002/eat.1054 · Cited by 38
Giordano, J., & Schultea, T. (2004) · Pain Physician · doi:10.36076/ppj.2004/7/141 · Cited by 38
Bhattacharya, A., Dang, H., Zhu, Q., Schnegelsberg, B., Rozengurt, N., Cain, G. R., Prantil, R. L., Vorp, D. A., Guy, N., Julius, D. J., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.5658-03.2004 · Cited by 36
Identification and importance of N-glycosylation of the human 5-hydroxytryptamine3A receptor subunit
Monk, S. A., Williams, J. M., Hope, A. G., & Barnes, N. M. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.06.034 · Cited by 34
Fibromyalgia treatment with intravenous tropisetron administration.
Stratz, T., Färber, L., Varga, B., Baumgartner, C., Haus, U., & Müller, W. (2001) · PubMed · Cited by 34
Andresen, V., & Hollerbach, S. H. (2004) · Drug Safety · doi:10.2165/00002018-200427050-00001 · Cited by 33
Analgesic effects of 5‐HT3receptor antagonists
Riering, K., Rewerts, C., & Zieglgänsberger, W. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410006970 · Cited by 33
The interaction of R(+)- and S(-)-zacopride with PCPA to modify rodent aversive behaviour
Barnes, N. M., Costall, B., Ge, J., Kelly, M. E., & Naylor, R. J. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90142-q · Cited by 32
Characterization of 5-HT3 Receptor Mutations Identified in Schizophrenic Patients
Thompson, A. J., Sullivan, N. L., & Lummis, S. C. R. (2006) · Journal of Molecular Neuroscience · doi:10.1385/jmn:30:3:273 · Cited by 24
Self-citationChannel-forming peptide modulates transepithelial electrical conductance and solute permeability
Broughman, J. R., Brandt, R., Hastings, C., Iwamoto, T., Tomich, J. M., & Schultz, B. D. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00426.2002 · Cited by 24
Sessoms-Sikes, J. S., Hamilton, M. E., Liu, L.-X., Lovinger, D. M., & Machu, T. K. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050542 · Cited by 24
Dawes, M. A., Johnson, B. A., Ma, J. Z., Ait‐Daoud, N., Thomas, S. E., & Cornelius, J. R. (2005) · Addictive Behaviors · doi:10.1016/j.addbeh.2005.07.004 · Cited by 22
Sandrini, M., Vitale, G., & Pini, L. A. (2002) · Pharmacology · doi:10.1159/000064343 · Cited by 22
Effects of Ethanol on Adenosine 5′‐Triphosphate–Gated Purinergic and 5‐Hydroxytryptamine3Receptors
Davies, D. L., Asatryan, L., Kuo, S. T., Woodward, J. J., King, B. F., Alkana, R. L., Xiao, C., Ye, J. H., Sun, H., Zhang, L., et al. (2006) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00023.x · Cited by 20
5-HT3 agonist 2-methylserotonin as a training drug in drug discrimination studies
Glennon, R. A., Young, R., & Dukat, M. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90111-r · Cited by 18
Hu, X., Hayrapetyan, V. Y., Gadhiya, J. J., Rhubottom, H. E., Lovinger, D. M., & Machu, T. K. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706685 · Cited by 16
Kurzwelly, D., Barann, M., Kostanian, A., Combrink, S., B�nisch, H., thert, M. G., & Br�ss, M. (2004) · Pharmacogenetics · doi:10.1097/00008571-200403000-00004 · Cited by 15
The, G. K. H., Prins, J. B., Bleijenberg, G., & van der Meer, J. W. M. (2003) · PubMed · Cited by 13
Thompson, A. J., Zhang, L., & Lummis, S. C. R. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-080-5_14 · Cited by 13
Self-citationNew and emerging treatments for irritable bowel syndrome and functional dyspepsia
Talley, N. J. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.1.91 · Cited by 7
Safety and Tolerability of Tegaserod in Irritable Bowel Syndrome Management
Berardi, R. R. (2004) · Journal of the American Pharmacists Association · doi:10.1331/154434504322713228 · Cited by 6
Cited by
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895
Serotonin Receptors – From Molecular Biology to Clinical Applications
PYTLIAK, M., VARGOVÁ, V., MECHÍROVÁ, V., & FELŠÖCI, M. (2011) · Physiological Research · doi:10.33549/physiolres.931903 · Cited by 318
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Self-citationThe 5-HT3 receptor – the relationship between structure and function
Barnes, N. M., Hales, T. G., Lummis, S. C. R., & Peters, J. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.003 · Cited by 258
Self-citationThe serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Metadata
- Authors
- Thompson, A. J., & Lummis, S. C.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2007-03-20
- Volume
- 11
- Issue
- 4
- Pages
- 527-540
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W1819750950
- Cited by
- 257
- References
- 109
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.